StockData
Alumis Inc. logo

Alumis Inc. (ALMS) stock

ALMSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 6/30
$6.73−0.16 (-2.32%)

Close on Oct 30, 2026Market cap $871.10MP/E –Yield –

Earnings

Alumis's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Nov 12, 2026
Q3 FY2026 · estimated, during market hours
Revenue, Q2 FY2026
$1.70M
-37.0% on a year earlier
EPS, Q2 FY2026
–
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Alumis's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q3 FY2026ended Sep 30, 2026Nov 12, 2026Expected––––
Q2 FY2026ended Jun 30, 2026Aug 13, 2026during market hours$1.70M-37.0%–Release
Q1 FY2026ended Mar 31, 2026May 14, 2026during market hours$1.70M-90.2%–Release
Q4 FY2025ended Dec 31, 2025Mar 19, 2026during market hours–––Release
Q3 FY2025ended Sep 30, 2025Nov 13, 2025during market hours$2.10M––Release
Q2 FY2025ended Jun 30, 2025Aug 13, 2025during market hours$2.70M––Release
Q1 FY2025ended Mar 31, 2025May 14, 2025during market hours$17.40M––Release
Q4 FY2024ended Dec 31, 2024Mar 19, 2025during market hours–––Release
Q3 FY2024ended Sep 30, 2024Nov 13, 2024during market hours–––Release
Q2 FY2024ended Jun 30, 2024Aug 13, 2024during market hours–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Alumis has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Alumis puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Alumis filed with the SEC as exhibits to Form 8-K or 6-K

  1. Alumis Announces Topline Results from Envudeucitinib
    News
  2. 8-K exhibit EX-99.2
    News
  3. Alumis Reports Second Quarter 2026 Financial Results and
    Results
  4. Envudeucitinib Long-term Data Positioned to
    News
  5. 8-K exhibit EX-99.1
    News
  6. Alumis Reports First Quarter 2026 Financial Results and
    Results
  7. and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as
    News
  8. Envudeucitinib (ESK-001) in Moderate-to-Severe Plaque
    News
  9. Alumis Reports Year End 2025 Financial Results and Highlights
    Results
  10. Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program
    News
  11. 8-K exhibit EX-99.2
    News
  12. Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
    Results
  13. 8-K exhibit EX-99.1
    News
  14. Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update
    Results
  15. Alumis Completes Merger with ACELYRIN
    News